Phase 3
N=72
Pericoital Oral Contraception With Levonorgestrel
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT00922233 ↗Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Oct 2013
Primary outcome: Primary: Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) — 22.4 pregnancies per 100 woman years
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- levonorgestrel (Drug)
- Age
- Pediatric, Adult
- Sex
- Female
- Sponsor
- FHI 360
- Primary completion
- Nov 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) |
22.4 | — |
| PRIMARY Participant Report of Adverse Events. |
45 | — |
| SECONDARY Acceptability Based on Bleeding Patterns Reported |
43 | — |
Summary
A prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel
Eligibility Criteria
Inclusion Criteria
Each woman enrolled in the trial must meet the following inclusion criteria:
- Competent to provide informed consent to participate in the trial and has done so.
- At least the minimum age is 18 to 45 years old.
- Had sex 1 to 4 days in past month and expects to continue at that frequency for the next 6.5 months.
- At low risk for sexually transmitted infection (STI), operationally meaning that neither she nor her partner to her knowledge has had any of the following:
- More than one sexual partner currently or any expectation of having more than one sexual partner in the next 6.5 months
- Diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
- Treatment for a STI within the past 6 months, excluding recurrent genital herpes or condyloma
- Sharing of illicit injection drug equipment ever in the past.
- Willing to use the study regimen as her only contraceptive method for the next 6.5 months (except that she may also use condoms if needed for protection from STIs).
- Wants to avoid pregnancy for at least the next 6.5 months.
- Willing to accept an uncertain risk of pregnancy during the study.
- Gives correct answers to the informed consent quiz.
- Willing and able to follow all study requirements.
Exclusion Criteria
To be eligible for enrollment, a woman must not meet any of the following exclusion criteria:
- Pregnant as verified by a pregnancy test at enrollment.
- Has an indication of current subfecundity, specifically:
- Her last pregnancy ended within the last 8 weeks, or she has had fewer than two menstrual periods since resolution of last pregnancy
- She has not had normal monthly menses for the past 2 months
- She is currently breastfeeding
- She has used any hormonal contraceptive other than emergency contraceptive pills since the onset of her last menstrual period
- Has received an injection of a long term injectable contraceptive in the last 9 months
- Currently has an intrauterine device
- Has had a sterilization procedure or ectopic pregnancy
- Has been diagnosed by a clinician as having a fertility problem
- Her partner has had a sterilization procedure or infertility diagnosis, to her knowledge.
- She currently has known contraindications to progestin-only pills, specifically including the following conditions:
- Unexplained abnormal vaginal bleeding
- Deep venous thrombosis or pulmonary embolus
- Active viral hepatitis
- Decompensated cirrhosis
- Liver tumor
- History of breast cancer within the past 5 years.
- Has a breast mass on examination.
- Has a personal or family history suggestive of predisposition to thrombosis.
- Has a serious contraindication to pregnancy (medical condition or use of chronic medication such as isotretinoin or thalidomide).
- Taking drugs that are known to interact with progestins (such as rifampicin or anticonvulsant medications).
- Has previously participated in this study.
- Currently participating in another medical research study.
- The site investigator or designee perceives another reason to exclude her from the trial.
Data sourced from ClinicalTrials.gov (NCT00922233). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.